Skye Bioscience Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Skye Bioscience, Inc. (SKYE) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-26.57-37.64-19.48-8.52-6.56
Depreciation & Amortization0.300.120.110.030.00
Stock Based Compensation8.320.990.630.870.30
Change in Working Capital-2.63-0.47-0.760.650.09
Change in Accounts Payable-0.59-0.700.800.520.24
Change in Other Working Capital-2.041.586.820.59-0.15
Other Operating Activities-4.661.586.820.59-0.44
Net Cash from Operating Activities-25.24-13.95-12.74-6.47-6.05
Investing Activities
Capital Expenditures-1.60-0.01-0.03-0.09-0.01
Acquisitions0.001.085.310.000.00
Sales/Maturities of Investments1.360.000.000.000.00
Net Cash from Investing Activities-0.256.605.21-0.09-0.01
Financing Activities
Debt Repayment0.00-0.26-0.890.000.00
Common Stock Issued83.5611.730.006.066.99
Other Financing Activities0.01-0.010.00-0.94-0.85
Net Cash from Financing Activities83.5616.44-0.2113.086.70
Summary
Net Change in Cash58.089.09-7.746.510.64
Cash at Beginning of Period10.341.258.992.470.00
Cash at End of Period68.4210.341.258.990.00
Free Cash Flow-26.84-13.96-12.77-6.57-6.06
Supplemental Disclosures
Interest Paid0.430.200.330.040.12
Income Taxes Paid0.010.000.010.000.00